GlobeNewswire

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor

Share

Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor

  • New patent granted in the United States by the USPTO protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035
     
  • This patent strengthens the protection of lanifibranor in the United States

             
Daix (France), August 20, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the United States Patent and Trademark Office (USPTO) granted a new patent on August 20, 2019 that protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035.

This new patent further strenghens Inventiva’s patent portfolio for lanifibranor, the Company’s lead product candidate, in the United States, which already comprised a New Chemical Entity (NCE) patent and a patent protecting the use of lanifibranor in several diseases including non-alcoholic steatohepatitis (“NASH”).

Pierre Broqua, Ph.D., Chief Scientific Officer and cofounder of Inventiva, stated: “This new patent represents an important milestone in the development of lanifibranor for the treatment of fibrotic diseases, particularly NASH, and confirms the innovative approach that we are pursuing in this treatment area. It is an additional positive news for our lead drug candidate after the FDA’s decision in May to lift the target class clinical hold for lanifibranor, and the significant recent progress in patient enrollment in our NATIVE Phase IIb clinical study in NASH.”


About lanifibranor

Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory and beneficial metabolic changes in the body by activating all three peroxisome proliferator activated receptor (“PPAR”) isoforms, which are well characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan PPAR agonist in clinical development. Inventiva believes that lanifibranor’s moderate and balanced pan PPAR binding profile contributes to the favorable safety and tolerability profile that has been observed in clinical trials and pre clinical studies to date.

Inventiva is currently evaluating lanifibranor in a Phase IIb clinical trial for the treatment of non-alcoholic steatohepatitis (“NASH”), a common and progressive chronic liver disease, for which there is currently no approved therapy.


About Inventiva  

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of diseases with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.

Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates – lanifibranor and odiparcil – in non-alcoholic steatohepatitis (“NASH”) and mucopolysaccharidosis (“MPS”), respectively, as well as a deep pipeline of earlier stage programs.

Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease. Inventiva is currently evaluating lanifibranor in a Phase IIb clinical trial for the treatment of this disease for which there are currently no approved therapies.

Inventiva is also developing odiparcil, a second clinical‑stage asset, for the treatment of patients with MPS, a group of rare genetic disorders. The Company is currently investigating odiparcil in a Phase IIa clinical trial for the treatment of patients with the MPS VI subtype.

In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. The Company has established two strategic partnerships with AbbVie and Boehringer Ingelheim in the areas of autoimmune diseases and idiopathic pulmonary fibrosis (“IPF”) respectively. AbbVie has started the clinical development phase of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. Both collaborations entitle Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the partnerships.

The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology a well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, around 60% of which are proprietary, as well as a wholly‑owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (Euronext: IVA – ISIN: FR0013233012). www.inventivapharma.com  


Contacts  

Inventiva
Frédéric Cren
Chairman & CEO
info@inventivapharma.com
+33 3 80 44 75 00


Brunswick Group
Yannick Tetzlaff / Tristan Roquet Montegon
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83


LifeSci Advisors

Monique Kosse

Investor relations

monique@lifesciadvisors.com

+1 212 915 3820


Important Notice

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the “Document de référence" filed with the Autorité des Marchés Financiers on April 12, 2019 under n° R.19-006 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Volta Finance Limited : Net Asset Value as at 31 May 2020 (Replacement)15.7.2020 18:00:00 CESTPress release

Volta Finance Limited (VTA / VTAS) – May 2020 monthly report NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 15 July 2020 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for May. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). The following amendments have been made to the Net Asset Value as at 31 May 2020 announcement released on 10 June 2020 at 17:00:00hrs (BST), to subtract from the Net Asset Value the first interim dividend of €0.10 per share declared by the Company as the ex-dividend date was 21 May 2020. Volta’s NAV as at the end of May 2020 has been adjusted from €204.6m to €200.9m and the NAV per share from €5.59 to €5.49. The full amended text is shown below. PERFORMANCE and PORTFOLIO ACTIVITY May was the second month of good performance after April, helping further to recover the mark-to-m

Vallourec : Appointment of Claire Langelier as Group General Counsel15.7.2020 18:00:00 CESTPress release

Appointment of Claire Langelier as Group General Counsel of Vallourec Boulogne-Billancourt (France), July 15, 2020 – Vallourec announces the appointment of Claire Langelier as Group General Counsel. She is part of the Executive Committee and Secretary of the Supervisory Board. Claire is responsible for Legal and Sustainable Development. She reports to Olivier Mallet, Member of the Management Board and Chief Financial Officer. Claire started her career in the law firm Latournerie Wolfrom & Associés in Paris, where she spent 13 years in the Corporate, Merger and Acquisitions and Private Equity Department. In 2013, she joined Econocom as Senior Legal Counsel, in charge of Corporate, Merger and Acquisitions. She joined Vallourec in 2015 and was previously Senior Legal Director in charge of Group Governance, Stock Exchange and Financing Law. Claire Langelier holds a Master of Corporate Business Law from Paris IX-Dauphine and a Master from the Institute of Business Management, IAE. Paris I-S

Agfa-Gevaert: Liechtensteinische Landesbank AG Publication of a transparency notification – Regulated information15.7.2020 17:40:00 CESTPress release

(Article 14 of the law of May 2, 2007 on the disclosure of significant shareholdings) Mortsel, Belgium – July 15, 2020 – 5.40 p.m. CET According to Agfa-Gevaert NV’s bylaws, the threshold as from which a shareholding needs to be disclosed, has been set at 3%, 5% and a multiple of 5%. In conformity with the Law of May 2, 2007 regarding the disclosure of significant shareholdings in listed companies, Agfa-Gevaert (Euronext: AGFB) discloses the following declaration: Liechtensteinische Landesbank AG has announced on July 15, 2020, that the function as fund management company of Classic Fund Management AG was transferred to LLB Fund Services AG, another fund management company, on July 1, 2020. As a result, LLB Fund Services AG holds a stake in Agfa-Gevaert NV as per July 1, 2020, of 7,833,294 voting rights or 4.56% (denominator is 171,851,042), thus crossing the threshold of 3% upwards. Full chain of controlled undertakings Liechtensteinische Landesbank AG, Städtle 44, 9490 Vaduz, Liechte

Ress Life Investments A/S: Ress Life Investments A/S publishes Net Asset Value (NAV)15.7.2020 17:10:00 CESTPress release

Ress Life Investments Holbergsgade 14, 2 tv DK-1057 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 15 July 2020 Corporate Announcement 26/2020 Ress Life Investments A/S publishes Net Asset Value (NAV). Ress Life Investments A/S publishes the Net Asset Value (NAV) per share and performance data as of 30 June 2020. NAV per share in USD: 1998.91 NAV per share in EUR: 1785.06 The performance during June was 1.30% in USD. The year-to-date net performance is 2.05% in USD. The return in June is positively affected by one policy paying out. Assets under management (AUM) was 188.7 million US dollars. Questions related to this announcement can be made to the company's AIF-manager, Resscapital AB. Contact person: Gustaf Hagerud gustaf.hagerud@resscapital.com Tel + 46 8 545 282 27 Note: The terms for subscription of shares, minimum subscription amount and redemption of shares are provided in the Articles of Association, Information Brochure and in the

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING15.7.2020 16:20:00 CESTPress release

SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING 2020-07-17 Transaction type:SEK CreditTender date:2020-07-17Time for submission of bids:10.30-11.00 (CEST)Payment date:2020-07-21Final repayment date2024-07-22Offered volume:50 billion SEKMinimum bid amount:10 million SEKMaximum bid amount:12.5 billion SEKMaximum number of bids from each participant: 1Interest rate:0.00 %Additional interest rate:0.10 per cent ALL APPROVED COUNTERPARTIES ARE INVITED TO SUBMIT VOLUME BIDS TO THE RIKSBANK (46-8-6966970) BY 11.00 ON JULY 17 2020, AT THE LATEST. CONFIRMATION ON E-MAIL: eol@riksbank.se Result of the auction will be published at 11.30 (CEST) on Tender date. Complete terms and conditions can be retrieved at http://www.riksbank.se